Testing oleogel-S10 for epidermolysis bullosa in Japanese patients
Part of Genetic & congenital, Skin clinical trials.
This trial tests a gel called oleogel-S10 on wounds caused by a rare skin condition called epidermolysis bullosa (EB). It is only for people of Japanese descent who have a specific type of EB called junctional or dystrophic EB. The gel is put on the wound to help it heal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 21 days old.
- You must have junctional or dystrophic epidermolysis bullosa (JEB or DEB).
- Both your biological parents and all four grandparents must be of Japanese descent.
- You must have at least 3 wounds that are not in the genital area, at least 5 cm apart, and some of them must have been open for at least 21 days but less than 9 months.
- If you are a woman who can get pregnant, you must avoid pregnancy during the study by using specific birth control methods or by not having sex.
- You and/or your legal guardian must understand the study and agree to follow all rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This study is a safety follow-up for people who already completed the SD-007 trial. It gives everyone SD-101, an experimental treatment for epidermolysis bullosa, to see how well it works over a longer period.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
Hear when a new Junctional Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.